Dr. Alicia Maria Terando, MD

Dr. Terando practices at Cedars-Sinai Medical Care Foundation in Beverly Hills, California.

Dr. Terando's NPI, 1396877080, was assigned on March 9, 2007. Dr. Terando graduated from MCP-Hahnemann College of Medicine in 1998. Dr. Terando holds California license A96086.

Dr. Terando's primary practice is Cedars-Sinai Medical Care Foundation, at 8501 Wilshire Blvd, Beverly Hills, CA 90211 in Los Angeles County. The practice phone is (310) 385-3200.

Dr. Terando's primary practice is Cedars-Sinai Medical Care Foundation in Beverly Hills, California. Dr. Terando is also affiliated with Huntington Hospital. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Terando to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Terando practices, 3 sites in all. Vendor and product names are available with a free account.

Surgical oncology is Dr. Terando's primary specialty in the NPI Registry, under taxonomy code 2086X0206X. Dr. Terando is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Terando's licenses on file in 3 states: California, Ohio and Michigan.

Dmand AI lists mastectomy among the conditions Dr. Terando treats.

CMS data shows 13 Medicare services from Dr. Terando across 1 procedure code in 2024, all of them office visits, for 33 Medicare patients. Medicare paid $1,022 for them. Every service was in an office.

CMS counts 33 Medicare patients who saw Dr. Terando in 2024. The largest group is 65 to 74, with 18 patients. 75% of them have cancer, and 64% have high cholesterol. Their average risk score is 1.05, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Terando's median patient age at 62, with 88% women.

Dr. Terando accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Terando as offering telehealth.

Mastectomy: 1 to 10 procedures (CMS shows small counts as a range)

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 43 papers to Dr. Terando, published from 2007 to 2023. 2018 was the busiest year, with 7. The most frequent topics are Melanoma, Skin Neoplasms and Breast Neoplasms. Dr. Terando has published most often in Ann Surg Oncol. Dr. Terando's most frequent co-authors are Georgia M. Beasley, MD, Mark B. Faries, MD and James W. Jakub, MD.

Dmand AI links Dr. Terando to 4 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Breast Neoplasms.

CMS Open Payments shows 5 general payments to Dr. Terando from 2 drug and device companies from 2018 to 2021. Food and beverage make up the largest share, 100% of the total. Stryker Corporation paid the most, $129.

Dmand AI lists 2 awards for Dr. Terando, most recently CMS Stage 1 EHR in 2013. Dr. Terando serves on Society of Surgical Oncology Melanoma Disease Site Working Group and American Society of Breast Surgeons Education Committee.

Dr. Terando graduated from MCP-Hahnemann College of Medicine in 1998. Dr. Terando is a member of ACS, ASBS, ASCO and SSO.

Dr. Terando is in network with 19 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 12. Check the plan with the practice before a visit.